Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.56 |
| ▸ | ACHE | P22303 | 6/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282166 | 0.89 | ACHE (0.53) | BCHEACHEDRD2CHRM4LMNA | |
| SCHEMBL5282667 | 0.87 | BCHE (0.55) | BCHEACHETACR1DRD2CHRM4 | |
| SCHEMBL5291489 | 0.87 | BCHE (0.52) | BCHEACHETACR1DRD2LMNA | |
| SCHEMBL5278655 | 0.87 | BCHE (0.59) | BCHEACHEDRD2 | |
| SCHEMBL5279913 | 0.85 | BCHE (0.60) | BCHEACHEDRD2 | |
| SCHEMBL5282975 | 0.85 | BCHE (0.47) | BCHEACHECHRM4 | |
| SCHEMBL5282971 | 0.85 | BCHE (0.47) | BCHEACHECHRM4 | |
| SCHEMBL5280165 | 0.85 | BCHE (0.49) | BCHEACHETACR1CHRM4KMT2A | |
| SCHEMBL5280283 | 0.84 | KMT2A (0.51) | BCHEACHETACR1KMT2A | |
| SCHEMBL5280288 | 0.84 | KMT2A (0.51) | BCHEACHETACR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | BCHE 1641/4885ACHE 3161/4885TACR1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.